Evotec is a holding company engaged as a drug discovery solutions company providing drug discovery capabilities to pharmaceutical and biotechnology companies as well as to academic institutions. These drug discovery solutions are provided in form of fee-for service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Co. is primarily involved in the areas of neuroscience, pain, metabolic diseases, oncology and inflammation. Co. provides its drug discovery activities under the banners of EVT Execute, EVT Integrate and EVT Innovate. Co.'s operations are divided into two segments: EVT Execute and EVT Innovate.
  • Ticker566480
  • ISINDE0005664809
  • SectorPharmaceuticals & Biotechnology
  • CountryGermany

Analysts

Thomas J. Schiessle

Kursrutsch eröffnet Kaufchance – Nachfrage ungebrochen – neue Einsatzfelder im Visier - H1/19 überzeugt

Nach dem sehr dynamischen Q1/19 erreichten die Q2/19-Erlöse mit € 103 Mio. das gleiche Niveau, die adj. EBITDA-Marge (zentraler KPI) im Q2/19 weitet sich nochmals, stärker als von uns erwartet. Das Gj. 2019 wird klar zweistellig wachsen - die Guidance wurde in diese Richtung konkretisiert. Die Nachfrage im Basisgeschäft ist und bleibt hoch, die Kundenbasis wird immer breiter. Das Auslaufen der Sanofi-Toulouse-Vereinbarung in Q3/20 dürfte somit deutlich überkompensiert werden. Durch die 100 %-Übernahme des US-Biologika-Experten Just Biotherapeutics wird eine strategische Lücke geschlossen und...

Thomas J. Schiessle

Sehr guter Start ins Gj. 2019 macht Hoffnung auf mehr

Mit einem sehr guten und von uns erwarteten Q1/19 startete das Gj. 2019, das auch im weiteren Verlauf kräftiges Wachstum verspricht. Die Kundenbasis wird breiter, die Nachfrage im Basisgeschäft ist und bleibt hoch (INDiGO, iPSC), ergänzt um mögliche Meilensteine (wichtige Studienstarts). Das Q1/19 startete mit einem Umsatzplus von 27 % ggü. Q1/18. Gutes Basisgeschäft; mehr Meilensteine und hohe F+E-Steuergutschriften kamen dazu.

Thomas J. Schiessle

Celgene-Zusammenarbeit fruchtet - 2019 startet sehr gut

Das Gj. 2018 war sehr erfreulich und auch das Gj. 2019 verspricht u.E. kräftiges Wachstum. Das Jahr startet lt. CEO Lanthaler (anl. 37 th. Annual J.P. Morgen HCC) mit einem sehr gut gefüllten Orderbuch. Am 17.12.18 wurde die Guidance 2018 für adj. EBITDA auf > 45 % Wachstum angehoben. Gründe dafür seien eine starke Entwicklung im laufenden Geschäft, das Erreichen wichtiger Meilensteine sowie ein Anstieg der sonstigen Erträge. Die zuvor gültige Guidance sah, trotz kräftiger Steigerung der F&E-Aufwendungen ein Umsatz-/adj. EBITDA-Plus von > 30% bzw. ca. 30 % vor. Am 21.05.18 konnte man mit Cel...

Thomas J. Schiessle

Celgene-Zusammenarbeit fruchtet - 2019 startet sehr gut

Das Gj. 2018 war sehr erfreulich und auch das Gj. 2019 verspricht u.E. kräftiges Wachstum. Das Jahr startet lt. CEO Lanthaler (anl. 37 th. Annual J.P. Morgen HCC) mit einem sehr gut gefüllten Orderbuch. Am 17.12.18 wurde die Guidance 2018 für adj. EBITDA auf > 45 % Wachstum angehoben. Gründe dafür seien eine starke Entwicklung im laufenden Geschäft, das Erreichen wichtiger Meilensteine sowie ein Anstieg der sonstigen Erträge. Die zuvor gültige Guidance sah, trotz kräftiger Steigerung der F&E-Aufwendungen ein Umsatz-/adj. EBITDA-Plus von > 30% bzw. ca. 30 % vor.

Igor Kim

Evotec AG : Estimates raised on brighter 2018 outlook for adj. EBITDA

>2018 estimates raised after upgrade to 2018 outlook - Evotec has increased its profitability guidance for 2018 and now expects a > 45% increase to its adjusted group EBITDA (previous est. around +30%) in 2018 vs last year (2017: € 58.4m). This increase primarily reflects Evotec’s strong business performance, which has boosted the margin contribution, and important scientific milestone achieved in the Q4 2018 as well as an increase in other operating income due to fac...

1 director bought

A director at Evotec Ag bought 10,000 shares at 19.000EUR and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

EVOTEC SE suffers a double requalification, which weighs heavily on its rating, now at Slightly Negative.

The independent financial analyst theScreener just downgraded the general evaluation of EVOTEC SE (DE), active in the Biotechnology industry. As regards its fundamental valuation, the title loses a star(s) and now shows 0 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Slightly Negative. As of the analysis date August 16, 2019, the closing price was EUR 18.98 and its target price was estimated at EUR 18.03.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Expert Corporate Governance Service (ECGS)

Evotec - AGM 19 June 2019

General: Evotec was founded 1993 in Hamburg, Today, the Company is a publicly listed drug discovery and development company that operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 3 April 2019, Novo Holdings A/S held between 10% and 15%, ROI Verwaltungsgesellschaft mbH/Roland Oetker, and The Goldman Sachs Group, Inc. each held between 5% and 10%, and Allianz Global Investors GmbH and DWS Investment GmbH each held between 3% and 5% of the Company's shares. Note th...

Dave Nicoski ...
  • Ross LaDuke

Int'l Insights: Bullish Developed Markets Stocks

Favor EAFE over EM The U.S. dollar remains elevated and as long as this remains the case we believe developed international equities (EAFE) will continue to outperform relative to emerging markets (MSCI EM)... see charts below. Below we highlight attractive and actionable themes within developed international: • Australia. Australia's All Ordinaries index exhibits bullish price and RS trends, a rarity when it comes to global markets considering most country-specific indexes display neutral or negative price trends. We highlight several Australian names, and would use recent broad market weak...

Dave Nicoski ...
  • Ross LaDuke

Int'l Insights: Developed Markets Leadership Chart Book

Europe in focus The U.S. dollar continues to grind marginally higher, and EM equities have suffered as a result. Meanwhile, RS for the MSCI EAFE index is bottoming when compared to the MSCI EM index, largely due to outperformance in Europe. With developed int'l markets beginning to outperform emerging markets, we recommend adding exposure to the developed int'l space. Below we highlight attractive and actionable themes within developed int'l: • Europe & Japan: Though this is an all-encompassing bottoms-up chart book for developed ex-U.S., make no mistake, the vast majority of today's buy rec...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Health Care outperforming globally -- overweight; India breaking out -- add exposure With the primary global ex-U.S. indexes MSCI EAFE, MSCI EM, and MSCI ACWI ex-U.S. continuing their sideways to downward consolidation from a price perspective, the importance of Sector, Group, and stock selection is critical. • Sector and Group Opportunities. Today we put the spotlight on the Health Care Sector, which is assuming a global leadership role as it separates itself from the other international Sectors. We also focus on the Communications Sector as it has seen steady relative strength ranking (RSR...

David Nikoski

Int'l Vital Signs: Actionable charts

In this product we rank the most positive and negative foreign stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts. For a trial to Vermilion Research visit our website at www.vermilioncap.com or contact our sales team at (952) 922-7500.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch